Trusopt  (U.S.N.L.M.)
Dosing 1 drop tid (monotherapy)     bid (additive therapy)
Chem Specs dorzolamide 2.0%
Quantities 5, 10ml
Cost 59.71/5ml
Class carbonic anhydrase inhibitor
Action Inhibition of carbonic anhydrase II in the ciliary processes presumably slows the
formation of bicarbonate with subsequent reduction in sodium and fluid transport.
Usage Indicated for elevated IOP of ocular hypertension or open-angle glaucoma.
Dorzolamide is a sulfonamide but one retrospective study1 suggested that topical
CIA's can be safely used despite a patient reported history of "sulfa alergy". Use
cautioned as sensitization may occur when sulfonamides are readministered.
Contraindications Hypersensitivity to any component of this product. Concomitant administration with
oral carbonic anhydrase inhibitors is not recommended.
Pediatric use Safety and effectiveness demonstrated in pediatric patients over 3 months of age.
Pregnancy Category C. Teratogenicity shown in rabbits at 37x the human dose but not at 16x.
0.0075% BAK preserved.
CAI's exert 70% of waking effect during sleep, prostaglandins 50% and timolol almost none.
Bitter taste sometimes encountered.
1. Guedes GB, et al. J Ocular Pharmacol Ther. 2013;29(5):456–61.     N.L.M. DailyMed page for Trusopt          PDR page for Trusopt